Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current Evidence and Future Directions - PubMed
7 days ago
- #treatment strategies
- #androgen deprivation therapy
- #prostate cancer
- Metastatic castration-sensitive prostate cancer (mCSPC) is a biologically heterogeneous disease with variable clinical outcomes.
- Treatment has evolved from androgen deprivation therapy (ADT) alone to combination therapies including chemotherapy and androgen receptor pathway inhibitors.
- Key trials like CHAARTED, STAMPEDE, and LATITUDE showed survival benefits with docetaxel or abiraterone added to ADT.
- Triplet therapies (ADT, docetaxel, and androgen receptor signaling inhibitors) further improve outcomes, but optimal patient selection is unclear.
- Advances in molecular profiling and imaging enable more precise patient stratification for personalized treatment.
- Emerging therapies include novel agents targeting DNA repair pathways and radiopharmaceuticals targeting prostate-specific membrane antigen.
- Understanding disease biology and patient characteristics is crucial for individualized care and better long-term outcomes.